Focused On-demand Library for Mediator of RNA polymerase II transcription subunit 17

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NVC6

UPID:

MED17_HUMAN

Alternative names:

Activator-recruited cofactor 77 kDa component; Cofactor required for Sp1 transcriptional activation subunit 6; Mediator complex subunit 17; Thyroid hormone receptor-associated protein complex 80 kDa component; Transcriptional coactivator CRSP77; Vitamin D3 receptor-interacting protein complex 80 kDa component

Alternative UPACC:

Q9NVC6; B3KN07; Q9HA81; Q9UNP7; Q9Y2W0; Q9Y660

Background:

Mediator of RNA polymerase II transcription subunit 17 plays a pivotal role in bridging gene-specific regulatory proteins with the basal RNA polymerase II transcription machinery. This ensures the regulated transcription of nearly all RNA polymerase II-dependent genes. Known by various names, including Mediator complex subunit 17 and Activator-recruited cofactor 77 kDa component, it is essential for conveying genetic information.

Therapeutic significance:

Linked to Microcephaly, postnatal progressive, with seizures and brain atrophy, understanding the role of Mediator of RNA polymerase II transcription subunit 17 could open doors to potential therapeutic strategies. Its involvement in severe developmental disorders underscores the importance of targeted research in uncovering treatment options.